Robin Jones, MBBS, MRCP, MD, Royal Marsden NHS Foundation Trust, London, UK, gives an update on gastrointestinal stromal tumor (GIST) studies. Firstly, Dr Jones discusses a Phase III trial INVICTUS (NCT03353753) which investigates the use of ripretinib vs placebo in patients who have received treatment with prior anticancer therapies. Secondly, Dr Jones discusses a Phase I trial (NCT02571036), this trial is a dose-escalation study which investigates the safety and tolerability of ripretinib in patients with advanced malignancies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).